: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) ( jbrooks@senesco.com ) (212) 850-5600 (732) 296-8400 SENESCO TECHNOLOG

TECHNOLOGIES ENTERS INTO AGREEMENT FOR UP TO $1.0 MILLION IN

BRUNSWICK, N.J. (July

("Senesco" or the "Company") (NYSE

today announced that, on July 9, 2009, the Company entered into a

definitive purchase agreement with Partlet Holdings Ltd. for the issuance and

sale of (i) up to 1,111,111 shares of its common stock (the "Shares") at a price

of $0.90 per share, (ii) warrants to purchase an aggregate of up to 1,000,000

shares of common stock, which warrants are exercisable immediately at an

exercise price of $0.01 per share (the "Partlet Series A Warrants") and

(iii) warrants to purchase an aggregate of up to 2,055,555 shares of common

stock, which warrants are exercisable 6 months from the date of issuance at an

exercise price of $0.60 per share (the "Partlet Series B

Warrants"). In connection with the private placement, the Company

anticipates that it will receive aggregate proceeds in the amount of

9, 2009, the Company closed on $950,000 of aggregate proceeds of the private

placement and, on that date, issued (i) a total of 1,055,555 Shares (ii) a

Partlet Series A Warrant to purchase 950,000 shares of the Company's common

stock and (iii) a Partlet Series B Warrant to purchase 1,952,778 shares of the

Company's common stock. The remaining $50,000 in proceeds cannot be closed

upon until the Company receives stockholder approval for certain aspects of the

transaction. Assuming all of the proceeds of the private placement can be

closed upon, the Company anticipates it will received gross proceeds equal to

no registration rights associated with the securities sold in the private

placement and no placement agent was used in connection with the private

primarily intends to utilize the proceeds of this private placement as an

initial step to help advance its research in multiple myeloma with the goal of

initiating a Phase I clinical trial.

pleased to have raised this additional capital," commented Joel Brooks, Chief

Financial Officer. "This funding allows us to remain focused on our

goal of filing an Investigational New Drug Application and initiating a Phase I

clinical trial for SNS-01."

press release shall not constitute an offer to sell or the solicitation of an

offer to buy, nor shall there be any sale of these securities in any state in

which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such state. The shares of

common stock have been sold pursuant to an exemption from state and federal

connection with the private placement, the Company will prepare a proxy

statement for the Company's stockholders to be filed with the Securities and

Exchange Commission (the "SEC"). The proxy statement will contain information

about the Company, the private placement and related matters. STOCKHOLDERS ARE

URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT IS AVAILABLE, AS IT WILL

CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE

MAKING A DECISION ABOUT APPROVING AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF

INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES.

addition to receiving the proxy statement from the Company by mail, shareholders

will be able to obtain the proxy statement, as well as other filings containing

information about the Company, without charge, from the SEC's website (http://www.sec.gov )

or, without charge, from the Company's website at www.senesco.com or

by directing such request to Senesco Technologies, Inc. 303 George

St., Suite 420, New Brunswick, New Jersey 08901 Attention: Joel

Company and its directors and executive officers and other members of management

and employees may be deemed to be participants in the solicitation of proxies.

Information concerning the Company and its directors and executive officers is

set forth in the Company's proxy statement and Annual Report on Form 10-K

previously filed with the SEC.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay

cell death in mammals (apoptosis) to determine if the technology is applicable

in human medicine. Accelerating apoptosis may have applications to development

of cancer treatments. Delaying apoptosis may have applications to certain

diseases inflammatory and ischemic diseases. Senesco takes its name from the

scientific term for the aging of plant cells: senescence. Delaying cell

breakdown in plants extends freshness after harvesting, while increasing crop

yields, plant size and resistance to environmental stress. The Company believes

that its technology can be used to develop superior strains of crops without any

modification other than delaying natural plant senescence. Senesco has partnered

with leading-edge companies engaged in agricultural biotechnology and earns

research and development fees for applying its gene-regulating platform

technology to enhance its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results could differ materially from such statements expressed or implied

herein as a result of a variety of factors, including, but not limited to: the

Company's ability to consummate this financing as well as additional financings;

the development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, as well as other

factors expressed from time to time in the Company's periodic filings with the

SEC. As a result, this press release should be read in conjunction with the

Company's periodic filings with the SEC. The forward-looking statements

contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.